Advances in the application of PET/CT molecular imaging probes to the treatment of breast cancer
10.3760/cma.j.cn112271-20241212-00474
- VernacularTitle:乳腺癌PET/CT分子影像探针应用进展
- Author:
Huayu LI
1
;
Jiaying SONG
1
;
Tao YE
1
;
Yucong WANG
1
;
Lianfu WANG
1
;
Qiang LI
1
Author Information
1. 宁波大学附属人民医院影像科，宁波 315040
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Radiopharmaceutical;
Positron emission tomography/computed tomography (PET/CT);
Molecular imaging
- From:
Chinese Journal of Radiological Medicine and Protection
2025;45(5):497-502
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer, a malignant tumor that significantly endangers women′s health, has shown a gradually rising incidence in recent years. Some breast cancer patients experienced poor prognosis. The commonly used imaging techniques for breast cancer include ultrasound, mammography, and magnetic resonance (MR), which suffer from certain limitations in accurately diagnosing and staging breast cancer. Positron emission tomography/computed tomography (PET/CT) enables tumor imaging at the cellular and molecular levels by utilizing radiolabeled molecular probes targeting different ligands. This technique facilitates precise localization and qualitative diagnosis of lesions to improve the staging accuracy, thereby reducing biopsy frequency and enhancing treatment effects for patients. Therefore, PET/CT has gradually developed into an essential imaging method for breast cancer in clinical practice. It plays a critical role in assessing the extent of lesion invasion, predicting immune subtypes, and estimating targeted therapy efficacy, holding promising application prospects. Recently, significant research breakthroughs have been achieved in this field. This review summarized the advances in clinical applications of different PET/CT molecular probes in the diagnosis and treatment of breast cancer, aiming to enhance the understanding of this aspect.
